La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Mangoceuticals Bilan de santé

Santé financière contrôle des critères 2/6

Mangoceuticals possède un total de capitaux propres de $13.8M et une dette totale de $187.5K, ce qui porte son ratio d'endettement à 1.4%. Son actif total et son passif total sont $15.2M et de $1.4M.

Informations clés

1.4%

Ratio d'endettement

US$187.50k

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$490.24k
Fonds propres	US$13.83m
Total du passif	US$1.41m
Total des actifs	US$15.24m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de MGRX ( $517.6K ) ne couvrent pas ses passifs à court terme ( $1.4M ).

Passif à long terme: Les actifs à court terme de MGRX ( $517.6K ) dépassent ses passifs à long terme ( $30.1K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: MGRX dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de MGRX a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: MGRX dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: MGRX dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 67.4 % chaque année

Mangoceuticals Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

Mangoceuticals, Inc. Provides Non-Compliance Update

Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLC

Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

Recent updates

Second quarter 2024 earnings released: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023)

Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating System

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Mangorx to Introduce “Mojo” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2023)

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

Mangoceuticals, Inc. Provides Non-Compliance Update

New major risk - Shareholder dilution

New major risk - Financial position

Mangoceuticals, Inc. Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment

Mangoceuticals, Inc. Accepting Pre Orders for its PRIME

High number of new and inexperienced directors

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. to Introduce “Prime”, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Mangoceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.6 million.

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLC

Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

New major risk - Market cap size

Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Mangoceuticals, Inc. Announces Upcoming Launch of Its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines